Temple closed a $54 million Series B to scale production of its biometric wearable platform, targeting professional team training rooms rather than retail shelves. The round values the company at approximately $200 million pre-money, according to two allocators briefed on the terms.

The funding arrives as professional leagues accelerate investment in real-time player monitoring systems. Temple's device tracks heart rate variability, lactate threshold proxies, and muscle oxygen saturation at 1,000 Hz sampling rates—roughly 10x the granularity of consumer fitness bands. The company already has pilot contracts with six NFL franchises, four Premier League clubs, and two NBA teams, though it declines to name them. Production capacity will expand from 12,000 units annually to 80,000 by Q3 2025.

What matters here is distribution strategy. Temple is skipping the Direct-to-Consumer grind that killed Whoop's margins and instead embedding with performance directors who control $2-4 million annual equipment budgets per team. The device requires a $12,000 annual subscription per athlete for cloud analytics and coaching dashboards—a price point that makes sense for a $150 million payroll but not a college club team. Temple's co-founder spent seven years at KINEXON, the German sensor firm that supplies the NBA's player-tracking cameras, and understands that league adoption creates a gravitational pull on NCAA programs within 18-24 months.

The revenue model also creates optionality for sponsors. If Temple achieves 15% penetration across the NFL's 1,696 active roster spots by 2027, that's roughly 250 players wearing Temple devices during games. Apparel brands pay $8-12 million annually for category exclusivity at that scale. Temple's Series A backer, a family office tied to a European football kit manufacturer, increased its position in this round.

Several agents have begun writing Temple compatibility clauses into boot and apparel deals for clients in contract years, anticipating that biometric data will become bargaining leverage in extensions. One NFC West quarterback's camp requested Temple's lactate data during offseason negotiations, arguing it demonstrated cardiovascular efficiency that extended his effective career window by two seasons. The team's front office pushed back, but the data entered the conversation.

Temple plans to hire 40 engineers by year-end and open a second manufacturing line in Austin. The company is also in talks with two European football leagues about exclusive sensor partnerships, which would require Temple to integrate with existing video-analysis platforms like Catapult and STATSports. Those deals typically include minimum purchase commitments of $6-8 million over three years.

Watch for Temple's first public team partnership announcement, likely during NFL minicamp season when performance staff budgets reset. Also watch which apparel brand moves first on a sensor integration deal—Nike and Adidas both have wearable R&D teams that have toured Temple's lab in the past 90 days. The company is meeting with NFLPA reps in March to discuss data-ownership protocols, which will determine whether Temple's information becomes collectively bargained.

The Series B was led by Declaration Partners, with participation from Elysian Park Ventures (Dodgers ownership vehicle) and Porsche Ventures. Temple's founder declined to comment on revenue but said the company is "cash-flow positive on existing contracts." That language usually means breakeven with upfront annual payments counted as revenue, which is standard for B2B wearable firms at this stage. The real test comes when contracts renew in 12-18 months and teams decide whether the data justified the spend.